MIR6082

Q-omics provides the consensus-scored MIR6082 profile across patient tissues and cancer cell-line models. MIR6082 expression is associated with patient survival in 2 of 34 cancer types, with the highest sampling consensus in STAD. Additionally, MIR6082 RNA expression shows 7,657 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight STAD, and LUSC as cancer lineages where MIR6082 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes MIR6082 survival associations across molecular data types. MIR6082 RNA expression shows survival associations in the most cancer types (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

MIR6082 data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	2	STAD (18)	view →

This table ranks reproducible MIR6082 RNA expression–survival associations across cancer types. High MIR6082 expression shows unfavorable associations in STAD and BLCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR6082 RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	IV	0.083	0.379	.001	18	view →
BLCA	DFS	Tertile	III,IV	0.159	0.572	.036	9	view →

Pink = unfavorable, green = favorable. all 2 lineages →

MIR6082-STAD (DFS)

Explore this curve interactively →